Conference Call with Indoco Remedies Management and Analysts on Q3FY25 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Indoco Remedies announced Q3FY25 results Revenue of Indoco Remedies is at Rs 3,649 million, as against Rs 4,484 million, Q3FY24. EBIDTA to net sales for the quarter is at Rs 201 million, compared to Rs 653 million, Q3FY24. Aditi Panandikar, Managing Director, Indoco Remedies, said: “Domestic Formulation Business continued to contribute in revenue growth, while the Export Formulation Business has been impacted by supply constraints from our sites that underwent planned shutdowns for enhancement of capacities and productivity.” Result PDF